【Abstract】Objective The aim of this study is to explore the relationship between fecal calprotectin and clinical features of irritable bowel syndrome (IBS).Methods From October to December 2017, 30 IBS patients (IBS group) were collected from the outpatient department of gastroenterology department of Chengdu Third People's Hospital, who had no abnormal colonoscopy and met the Rome IV diagnostic standard. 30 healthy controls were collected at the same time, and the content of calprotectin in feces was quantitatively detected by enzymelinked immunosorbent assay. ResultsThere was no significant difference in the content of calprotectin between IBS patients and healthy people (P<005). However, there was a significant correlation among the time of IBS, abdominal pain >6 months and defecation (P<005). Compared with the healthy population, the level of faecal calprotectin in IBS patients decreased significantly at the beginning of the disease (t=〖CD*3/5〗2621, P=0012), while the level of faecal calprotectin in patients with IBS in 15 years decreased even more (t=344, P=0002). At the same time, FC increased significantly in patients with abdominal pain> 6 months. Conclusions Fecal calprotectin was significantly associated with IBS symptoms such as the duration of IBS, abdominal pain＞6 months and watery stool.